DURHAM, N.C., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, Chief Executive Officer of Chimerix, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 4:15 p.m. ET at the Grand Hyatt Hotel in New York City.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix’s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates, including CMX669. Chimerix is also advancing a clinical candidate for norovirus infection, CMX521. For further information, please visit Chimerix’s website, www.chimerix.com.
CONTACT: Investor Relations: ir@chimerix.com or Jesse Baumgartner Stern Investor Relations Jesse@sternir.com 212-362-1200 Media: Becky Vonsiatsky W2O Group bvonsiatsky@w2ogroup.com 413-478-2003
